Research Analysts Set Expectations for uniQure Q3 Earnings

uniQure N.V. (NASDAQ:QURE) – Equities research analysts at William Blair boosted their Q3 2026 EPS estimates for uniQure in a report released on Wednesday, September 24th. William Blair analyst S. Corwin now anticipates that the biotechnology company will earn ($0.29) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($1.71) EPS.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%.

Other equities analysts have also issued reports about the stock. Chardan Capital raised their target price on shares of uniQure from $35.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald raised their target price on shares of uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday. Wells Fargo & Company raised their target price on shares of uniQure from $30.00 to $65.00 and gave the stock an “overweight” rating in a research report on Thursday. Stifel Nicolaus raised their target price on shares of uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Leerink Partners raised their target price on shares of uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 24th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $67.17.

uniQure Stock Performance

Shares of uniQure stock opened at $54.31 on Monday. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $2.98 billion, a P/E ratio of -13.85 and a beta of 0.13. The firm’s 50 day moving average is $17.44 and its two-hundred day moving average is $14.91. uniQure has a 52 week low of $4.45 and a 52 week high of $55.11.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 15,000 shares of the firm’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the sale, the chief financial officer owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 244,316 shares of company stock valued at $10,328,181. Corporate insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP lifted its holdings in uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after acquiring an additional 1,767,572 shares during the period. Nantahala Capital Management LLC lifted its holdings in uniQure by 3.8% in the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock valued at $29,213,000 after acquiring an additional 101,598 shares during the period. Aberdeen Group plc lifted its holdings in uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after acquiring an additional 535,163 shares during the period. Jefferies Financial Group Inc. acquired a new stake in uniQure in the second quarter valued at $29,217,000. Finally, JPMorgan Chase & Co. lifted its holdings in uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.